학술논문
Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma
Document Type
Journal Article
Author
Atsushi Ohno; Eisuke Murakami; Hatsue Fujino; Hiroshi Aikata; Kei Amioka; Kenichiro Kodama; Kensuke Naruto; Masami Yamauchi; Masanari Kosaka; Michio Imamura; Ryoichi Miura; Serami Murakami; Shigeki Yano; Shinsuke Uchikawa; Takashi Nakahara; Tomokazu Kawaoka; Wataru Okamoto; Yuki Shirane; Yumi Kosaka; Yusuke Johira; Yuwa Ando
Source
Internal Medicine. 2023, 62(12):1771
Subject
Language
English
ISSN
0918-2918
1349-7235
1349-7235
Abstract
To our knowledge, there have been no reports of first-line lenvatinib (LEN) and LEN re-challenge following atezolizumab/bevacizumab (Atezo-Bev) failure in the same patient. We herein report a patient with advanced hepatocellular carcinoma who failed either 1st line LEN and 2nd line Atezo-Bev, and successfully achieved complete response to LEN rechallenge with sequencial transcatheter arterial chemoembolization (TACE). This patient had a poor response to TACE before immunotherapy and introduction of molecular-targeted drugs but showed a good response to selective TACE after LEN rechallenge. Our findings suggest the need to reconsider the use of molecular-targeted drugs and TACE with advances in immunotherapy.